FDA Warns Against Use of Hydroxychloroquine in Non-Hospitalized COVID-19 Patients




WASHINGTON, D.C. — The Food and Drug Administration has cautioned consumers and health professionals against using hydroxychloroquine and chloroquine to treat non-hospitalized patients for COVID-19 or to prevent the virus, explaining that it can lead to life-threatening heart rhythm problems.

In an April 24 MedWatch Safety Alert, the agency noted that it authorized temporary use of the drugs “only in hospitalized patients with COVID-19 when clinical trials are not available, or participation is not feasible, through an Emergency Use Authorization (EUA).

Hydroxychloroquine and chloroquine are FDA-approved to treat or prevent malaria. Hydroxychloroquine is also FDA-approved to treat autoimmune conditions …






UPCOMING CONFERENCES




HarrisMartin's New Jersey Asbestos Litigation Conference

February 27, 2025 - New Brunswick, NJ
Hyatt Regency New Brunswick

MORE DETAILS



HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS